GCP
LAB icon

GSA Capital Partners’s Standard BioTools LAB Stock Holding History

GSA Capital Partners’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$325K Buy
353,471
+306,205
+648% +$371K 0.02% 1205
2025
Q4 		$61K Buy
+47,266
New +$63.5K 0.01% 1564
2025
Q3 		– Sell
-306,487
Closed -$368K – 1892
2025
Q2 		$368K Sell
306,487
-302,169
-50% -$335K 0.03% 1133
2025
Q1 		$657K Buy
608,656
+478,922
+369% +$672K 0.06% 608
2024
Q4 		$227K Buy
+129,734
New +$242K 0.02% 1354
2022
Q1 		– Sell
-101,494
Closed -$398K – 1632
2021
Q4 		$398K Buy
101,494
+57,589
+131% +$270K 0.05% 748
2021
Q3 		$289K Buy
+43,905
New +$289K 0.03% 1045
2021
Q2 		– Sell
-105,852
Closed -$478K – 1473
2021
Q1 		$478K Buy
105,852
+63,908
+152% +$351K 0.08% 379
2020
Q4 		$252K Sell
41,944
-40,959
-49% -$269K 0.04% 842
2020
Q3 		$616K Buy
+82,903
New +$572K 0.1% 283
2019
Q2 		– Sell
-61,910
Closed -$823K – 1597
2019
Q1 		$823K Buy
+61,910
New +$653K 0.08% 392
2014
Q1 		– Sell
-7,020
Closed -$269K – 1691
2013
Q4 		$269K Buy
+7,020
New +$207K 0.02% 1280

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

GSA Capital Partners's LAB Position: Q1 2026 in Review

GSA Capital Partners increased its Standard BioTools (LAB) stake by 648% in Q1 2026, buying an estimated $371K and bringing the position to 353,471 shares worth $325K. The position accounts for 0.02% of the portfolio, ranked #1205.

GSA Capital Partners first reported a position in LAB in Q4 2013 and has held it in 12 quarters since. The position peaked at $823K in Q1 2019. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • GSA Capital Partners held 353,471 shares of Standard BioTools worth $325K as of Q1 2026.
  • GSA Capital Partners bought 306,205 Standard BioTools shares in Q1 2026, an estimated $371K.
  • Standard BioTools made up 0.02% of GSA Capital Partners's portfolio in Q1 2026, its #1205 holding.
  • GSA Capital Partners first reported a position in Standard BioTools in Q4 2013 and has held it in 12 quarters since.
  • GSA Capital Partners's Standard BioTools position peaked at $823K in Q1 2019.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.